MALLINCKRODT PLC (MNK)
IE000O3L0NQ3 - Common Stock
MALLINCKRODT PLC
NYSEARCA:MNK (8/25/2023, 7:14:49 PM)
Premarket: 0.3505 +0.01 (+3.03%)0.3402
-0.06 (-14.97%)
Company Profile
Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
Company Info
MALLINCKRODT PLC
College Business & Technology Park, Cruiserath,, Blanchardstown
DUBLIN D15
CEO: Mark C. Trudeau
Employees: 2700
Website: https://www.mallinckrodt.com/
MNK News
4 months ago - Seeking AlphaMallinckrodt to discontinue StrataGraft due to slow uptake (OTCMKTS:MNKTQ)Mallinckrodt (MNKTQ) said Monday it was discontinuing its regenerative skin tissue product StrataGraft, which is used for the treatment of thermal burns. The dr
6 months ago - Seeking AlphaMallinckrodt emerges from bankruptcy (OTCMKTS:MNKTQ)Mallinckrodt emerges from bankruptcy with reduced debt and new ownership structure, ready to focus on strategic initiatives and product launches.
6 months ago - Yahoo FinanceUPDATE 1-Drugmaker Mallinckrodt emerges from bankruptcyDrugmaker Mallinckrodt said on Tuesday it has emerged from bankruptcy and reduced its total funded debt by about $1.9 billion. Mallinckrodt, which won court approval for its bankruptcy plan last month, said it is moving ahead with ample liquidity to execute its strategic priorities. Pursuant to the bankruptcy plan, ownership of the company will now be handed over to its lenders and all its equity shares would cease to exist.
%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FXYAQZ67D5NIB7OWVKRWK7CPVBM.jpg)
6 months ago - ReutersDrugmaker Mallinckrodt emerges from bankruptcyDrugmaker Mallinckrodt said on Tuesday it has completed its financial restructuring and emerged from bankruptcy.
Mallinckrodt, which won court approval for its bankruptcy plan last month, said it is moving ahead with ample liquidity to execute its strategic priorities. Pursuant to the bankruptcy plan, ownership of the company will now be handed over to its lenders and all its equity shares would cease to exist. Mallinckrodt, which makes branded and generic drugs, first filed for bankruptcy in 2020 to address its high debt load, litigation over its allegedly deceptive marketing of highly addictive generic opioids and drug pricing disputes.
7 months ago - Seeking AlphaMallinckrodt sees emerging from Chapter 11 by end of year (MNKTQ)Mallinckrodt has received approval from a US bankruptcy court for a reorganization plan that should allow it to emerge from Chapter 11 in Q4. Read more here.
MNK Twits
Here you can normally see the latest stock twits on MNK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
